U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505303) titled 'MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial' on March 05.
Brief Summary: The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Study Start Date: March 13
Study Type: INTERVENTIONAL
Condition:
Adult Obesity
Weight Management
Intervention:
DRUG: ECC4703
orally QD
DRUG: Placebo
orally QD
DRUG: Semaglutide
SC once weekly
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eccogene
Published by HT Digital Co...